Ryszard Podemski

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Stimulated peripheral production of interferon-gamma is related to fatigue and depression in multiple sclerosis

Anna Pokryszko‐Dragan, Irena Frydecka, Agata Kosmaczewska et al. · Clinical Neurology and Neurosurgery · 2012 · 65 citations

Clinical Disorders, Psychoneuroimmunology, Neurobiology Of Disease +11

Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis

Magdalena Szmyrka−Kaczmarek, Anna Pokryszko‐Dragan, Bartłomiej Pawlik et al. · Lupus · 2011 · 62 citations

Rheumatology, Ms Patients, Autoimmune Disease +14

Event-related potentials and cognitive performance in multiple sclerosis patients with fatigue

Anna Pokryszko‐Dragan, Mieszko Zagrajek, Krzysztof Słotwiński et al. · Neurological Sciences · 2016 · 50 citations · Full text